Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Starpharma Holdings Announces DEP irinotecan Boosts Immuno-Oncology in Colon Cancer Models

29 Jun 2020  |  09:22:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: DEP irinotecan boosts immuno-oncology in colon cancer models

Starpharma Holdings announced its SN-38 nanoparticle, DEP irinotecan in combination with an immunooncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC mode. IO agents are important treatments in several major cancers and the market for these agents is expected to exceed US$55bn by 2025, and include Merck's Keytruda, BMS' Yervoy and AstraZeneca's Imfinzi.

Please click here for full details

See more ASX300 News Announcements